These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21612542)

  • 1. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.
    Cariani E; Villa E; Rota C; Critelli R; Trenti T
    Clin Chem Lab Med; 2011 Aug; 49(8):1247-1256. PubMed ID: 21612542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.
    Lee TH; Tillmann HL; Patel K
    Mol Diagn Ther; 2014 Feb; 18(1):25-38. PubMed ID: 24022240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.
    Riva E; Scagnolari C; Turriziani O; Antonelli G
    Clin Microbiol Infect; 2014 Dec; 20(12):1237-45. PubMed ID: 25273834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.
    Asthana M; Sahu SK; Kumar A; Mohanty S; Chakrabarti S; Das P; Chattopadhya NR; Chatterjee K; Singh SP; Rajasubramaniam S; Choudhuri T
    Curr Drug Metab; 2018; 19(3):215-223. PubMed ID: 29380700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
    Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
    J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment.
    Mizokami M
    J Gastroenterol Hepatol; 2012 Mar; 27(3):425-9. PubMed ID: 22168813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.
    Holmes JA; Desmond PV; Thompson AJ
    Clin Liver Dis; 2011 Aug; 15(3):497-513. PubMed ID: 21867933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
    Seto WK; Tsang OT; Liu K; Chan JM; Wong DK; Fung J; Lai CL; Yuen MF
    J Viral Hepat; 2013 Jul; 20(7):470-7. PubMed ID: 23730840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.
    Takahashi H; Mizuta T; Oeda S; Isoda H; Nakashita S; Kawaguchi Y; Izumi N; Hirai M; Kurose K; Iwane S; Eguchi Y; Kimura S; Anzai K; Ozaki I
    J Viral Hepat; 2013 Apr; 20(4):e124-6. PubMed ID: 23490380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.
    Mangia A; Mottola L; Santoro R
    World J Gastroenterol; 2013 Dec; 19(47):8924-8. PubMed ID: 24379617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
    Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
    Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genome-wide association study on and the clinical application to chronic hepatitis C].
    Sugiyama M; Mizokami M
    Uirusu; 2011 Jun; 61(1):15-24. PubMed ID: 21972552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.
    Bellanti F; Vendemiale G; Altomare E; Serviddio G
    Clin Dev Immunol; 2012; 2012():849373. PubMed ID: 22966241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.
    Ahlenstiel G; Booth DR; George J
    J Gastroenterol; 2010 Sep; 45(9):903-10. PubMed ID: 20635099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
    Firpi RJ; Dong H; Clark VC; Soldevila-Pico C; Morelli G; Cabrera R; Norkina O; Shuster JJ; Nelson DR; Liu C
    Liver Int; 2013 Jan; 33(1):72-8. PubMed ID: 23107586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualization of chronic hepatitis C treatment according to the host characteristics.
    Gatselis NK; Zachou K; Saitis A; Samara M; Dalekos GN
    World J Gastroenterol; 2014 Mar; 20(11):2839-53. PubMed ID: 24659876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.
    Venegas M; Brahm J; Villanueva RA
    Ann Hepatol; 2012; 11(6):827-37. PubMed ID: 23109445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection.
    Rembeck K; Lagging M
    Pharmacogenomics; 2015; 16(10):1179-88. PubMed ID: 26250055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic polymorphisms as predictors of response to antiviral treatment in chronic hepatitis C virus infection].
    Pár A
    Orv Hetil; 2011 May; 152(22):876-81. PubMed ID: 21565755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.